DBV Technologies S.A.: DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq
Châtillon, France, July 30, 2026 DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Capital Market: DBVT) (the "Company"), a late-stage biopharmaceutical company, today announced that, pursuant to the Company's At-The-Market Program established on September 1, 2025 and included in a new registration statement and accompanying prospectus filed on July 27, 2026, (the...
How this was made
The 30-second read
Why it matters
The company agreed to issue and sell new ordinary shares via ADSs for gross proceeds of about $50 million at $13.67 per ADS, with expected delivery on Aug 3, 2026, and disclosed dilution of about 5.82% upon completion.
Market read
Traders should price in disclosed dilution and the near-term execution date, while monitoring whether the ATM pace accelerates or slows.
What to watch
The actual market impact depends on the execution pace of ADS sales under the ATM, investor appetite for discounted issuance, and whether the company pairs financing with near-term clinical catalysts.
Background
DBV Technologies launched an at-the-market program in 2025 and filed related registration materials with the SEC in July 2026.
Ticker impact
DBV Technologies agreed to sell about $50 million of ADSs via its Nasdaq at-the-market program, implying near-term dilution and funding impact.
Likely downward or volatile bias around announcement and execution, with sensitivity to pace of ADS sales and any concurrent clinical/financing signals.
The article discloses the ATM issuance size (~$50m gross), ADS pricing ($13.67), and dilution (~5.82%), which directly affects near-term per-share value and float/supply dynamics.
Market effects
Late-stage biotech with ATM programs may face persistent discounting due to recurring dilution risk, especially when priced at a discount to prior Euronext levels.
Cross-listing mechanics (Nasdaq ADS vs Euronext ordinary shares) can amplify FX and discount effects on trading spreads.
Limited broader market impact; primarily affects DBV Technologies’ capital structure and near-term liquidity/float.
Counterpoint
If the company uses proceeds to de-risk late-stage trials or extend runway, the ATM could be viewed as a financing enabler rather than purely negative dilution.
Key entities
- issuerDBV Technologies
Late-stage biopharmaceutical company selling ADSs under an at-the-market program on Nasdaq.
- investorRA Capital Management, L.P
Named as the counterparty receiving ADSs through the sales agent arrangement.
- sales_agentCitizens JMP Securities, LLC
Acting as sales agent for the ATM ADS sales.